Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Cash (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Cash for 16 consecutive years, with -$509000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 90.23% to -$509000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $322000.0, a 102.05% increase, with the full-year FY2025 number at $322000.0, up 102.05% from a year prior.
  • Change in Cash was -$509000.0 for Q4 2025 at Anika Therapeutics, down from $4.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $5.6 million in Q3 2023 to a low of -$14.7 million in Q2 2023.
  • A 5-year average of -$1.9 million and a median of -$1.3 million in 2021 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: plummeted 1474.51% in 2023, then surged 1162.33% in 2025.
  • Anika Therapeutics' Change in Cash stood at $3.4 million in 2021, then crashed by 142.52% to -$1.4 million in 2022, then skyrocketed by 252.83% to $2.2 million in 2023, then tumbled by 335.06% to -$5.2 million in 2024, then surged by 90.23% to -$509000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Change in Cash are -$509000.0 (Q4 2025), $4.8 million (Q3 2025), and -$204000.0 (Q2 2025).